Stella Therapeutics had been workig on development of novel small molecules (ST drugs) that hold the promise of treating malignant tumors through a unique mechanism of action by initially blocking the migration and proliferation of tumor cells, and then selectively killing them through the induction of apoptosis (programmed cell death). Principals of the firm had been addessing application of their technology to Glioblastoma Multiforme (GBM), the most common and deadliest malignant brain tumor, while maintaining patient quality of life. It is reported that the firm likely closed its doors in late 2017
